OBJECTIVE: T-cell-mediated autoimmunity may be involved in some cases of idiopathic neutropenia. We hypothesized that a precise T-cell receptor repertoire analysis may uncover cytotoxic T-cell (CTL) expansions that are less pronounced than those seen in T large granular lymphocyte leukemia (T-LGL), but are pathophysiologically analogous and thus can serve as markers of a T-cell-mediated process. MATERIALS AND METHODS: Using rational algorithms for T-cell receptor analysis and in vivo tracking of CTL responses previously established in our laboratory, we studied patients with unexplained chronic neutropenia (n = 20), T-LGL (n = 15), and healthy controls (n = 12). We further investigated the involvement of soluble inhibitory factors by coculture assays. To determine the level of immune activation, we studied interferon-gamma expression in CD8(+)cells using Taqman polymerase chain reaction. RESULTS: Fifteen expanded (immunodominant) CTL clones were detected in 12 of 20 patients. In comparison to LGL leukemia, these clones were less immunodominant, but clearly discernible from subclinical lymphoproliferations in controls. As a surrogate of cytotoxic activity, we found markedly increased production of interferon-gamma in most of the neutropenia patients, irrespective of the presence of immunodominant CTL clones. CONCLUSIONS: These results suggest that, while immunodominant CTL clones are detectable in a proportion of patients only, CTL-mediated pathophysiology may be a general mechanism operating in idiopathic neutropenia. Oligogoclonal CTL expansions in chronic neutropenia may indicate an ongoing autoimmune process, while highly polarized monoclonalities in a subset of neutropenic LGL patients may represent the "extreme" end of the clonal continuum.
OBJECTIVE: T-cell-mediated autoimmunity may be involved in some cases of idiopathic neutropenia. We hypothesized that a precise T-cell receptor repertoire analysis may uncover cytotoxic T-cell (CTL) expansions that are less pronounced than those seen in T large granular lymphocyte leukemia (T-LGL), but are pathophysiologically analogous and thus can serve as markers of a T-cell-mediated process. MATERIALS AND METHODS: Using rational algorithms for T-cell receptor analysis and in vivo tracking of CTL responses previously established in our laboratory, we studied patients with unexplained chronic neutropenia (n = 20), T-LGL (n = 15), and healthy controls (n = 12). We further investigated the involvement of soluble inhibitory factors by coculture assays. To determine the level of immune activation, we studied interferon-gamma expression in CD8(+)cells using Taqman polymerase chain reaction. RESULTS: Fifteen expanded (immunodominant) CTL clones were detected in 12 of 20 patients. In comparison to LGL leukemia, these clones were less immunodominant, but clearly discernible from subclinical lymphoproliferations in controls. As a surrogate of cytotoxic activity, we found markedly increased production of interferon-gamma in most of the neutropeniapatients, irrespective of the presence of immunodominant CTL clones. CONCLUSIONS: These results suggest that, while immunodominant CTL clones are detectable in a proportion of patients only, CTL-mediated pathophysiology may be a general mechanism operating in idiopathic neutropenia. Oligogoclonal CTL expansions in chronic neutropenia may indicate an ongoing autoimmune process, while highly polarized monoclonalities in a subset of neutropenic LGLpatients may represent the "extreme" end of the clonal continuum.
Authors: R Handgretinger; A Geiselhart; A Moris; R Grau; O Teuffel; W Bethge; L Kanz; P Fisch Journal: N Engl J Med Date: 1999-01-28 Impact factor: 91.245
Authors: R Schwab; P Szabo; J S Manavalan; M E Weksler; D N Posnett; C Pannetier; P Kourilsky; J Even Journal: J Immunol Date: 1997-05-01 Impact factor: 5.422
Authors: Min Shi; Horatiu Olteanu; Dragan Jevremovic; Rong He; David Viswanatha; Heidi Corley; Pedro Horna Journal: Mod Pathol Date: 2020-05-13 Impact factor: 7.842
Authors: Jahnavi Aluri; Alicia Bach; Saara Kaviany; Luana Chiquetto Paracatu; Maleewan Kitcharoensakkul; Magdalena A Walkiewicz; Christopher D Putnam; Marwan Shinawi; Nermina Saucier; Elise M Rizzi; Michael T Harmon; Molly P Keppel; Michelle Ritter; Morgan Similuk; Elaine Kulm; Michael Joyce; Adriana A de Jesus; Raphaela Goldbach-Mansky; Yi-Shan Lee; Marina Cella; Peggy L Kendall; Mary C Dinauer; Jeffrey J Bednarski; Christina Bemrich-Stolz; Scott W Canna; Shirley M Abraham; Matthew M Demczko; Jonathan Powell; Stacie M Jones; Amy M Scurlock; Suk See De Ravin; Jack J Bleesing; James A Connelly; V Koneti Rao; Laura G Schuettpelz; Megan A Cooper Journal: Blood Date: 2021-05-06 Impact factor: 25.476
Authors: David C Dale; Audrey Anna Bolyard; James A Shannon; James A Connelly; Daniel C Link; Mary Ann Bonilla; Peter E Newburger Journal: Blood Adv Date: 2022-07-12